Inclusion Criteria:

          -  Documented diagnosis of multiple myeloma (MM) based on standard IMWG criteria.

          -  Measurable disease at screening as defined per protocol.

          -  Has received at least 2 prior lines of therapy as described in the protocol.

          -  Has had documented disease progression on or within 60 days after completion of the
             last therapy.

          -  Has received at least 2 consecutive cycles of lenalidomide and be relapsed/refractory
             to lenalidomide, as defined per protocol.

          -  Has received at least 2 consecutive cycles of a proteasome inhibitor (PI).

          -  Has MM positive for t(11;14).

          -  An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
             2.

          -  Laboratory values (liver, kidney and hematology laboratory values) that meet criteria
             as described per protocol.

        Exclusion Criteria:

          -  History of treatment with venetoclax or another B-Cell Lymphoma (BCL)-2 inhibitor or
             pomalidomide.

          -  History of other active malignancies, including myelodysplastic syndromes (MDS),
             within the past 3 years (exceptions described in the protocol).

          -  Evidence of ongoing graft-versus-host disease (GvHD) if prior stem cell transplant
             (SCT).

          -  Prior treatment with any of the following: allogeneic or syngeneic SCT within 16 weeks
             prior to randomization; or autologous SCT within 12 weeks prior to randomization.

          -  Known central nervous system involvement of MM.

          -  Concurrent conditions as listed in the protocol.